Moreover, the SMAD4 loss was also associated with worse clinical outcome and resistance to fluoropyrimidine-based chemotherapy [119], implicating its use as a prognostic marker in the CRC patients [120]. This evidence concerns the gene SMAD4 and colorectal carcinoma.